Physician profile
Adan Alvarez
NPI 1821343963
$1,348.17
in general payments reported to CMS, 2019-2025
22 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.01 · 2020: $136 · 2021: $289 · 2022: $354 · 2023: $361 · 2024: $54.04 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $526.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $299.63 | 2023-2025 | Dexcom G6 Transmitter |
| Cardiovascular Systems INC. | $151.03 | 2022 | |
| Abbvie INC. | $137.56 | 2021-2023 | Qulipta |
| Eisai INC. | $111.12 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.01 | 2020-2021 | |
| Alkermes, INC. | $107.03 | 2019-2023 | Vivitrol |
| Bausch Health US, LLC | $64.73 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.25 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $42.89 | 2024-2025 | |
| Verity Pharmaceuticals INC. | $30.24 | 2024 | Tlando |
| Teva Pharmaceuticals USA, INC. | $28.64 | 2021 | |
| Janssen Biotech, INC. | $26.48 | 2025 | Balversa, Akeega, Erleada |
| Novo Nordisk INC | $24.36 | 2023 | Ozempic |
| Indivior INC. | $24.33 | 2021 | |
| Sk Life Science, INC. | $23.47 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $20.66 | 2019 | |
| Revance Therapeutics, INC. | $19.27 | 2025 | Daxxify |
| Lilly USA, LLC | $18.85 | 2023 | Mounjaro |
| Sun Pharmaceutical Industries INC. | $18.20 | 2020 | |
| Genentech USA, INC. | $17.26 | 2020 | |
| Uswm, LLC | $17.14 | 2021 | |
| Gilead Sciences, INC. | $13.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adan Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.